Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials

被引:43
作者
Zhang, Chuan-Hai [1 ,2 ,3 ]
Xu, Ge-Liang [1 ,3 ]
Jia, Wei-Dong [1 ,3 ]
Li, Jian-Sheng [1 ,3 ]
Ma, Jin-Liang [1 ,3 ]
Ge, Yong-Sheng [1 ,3 ]
机构
[1] Anhui Med Univ, Anhui Prov Hosp, Ctr Study Liver Canc, Hefei, Anhui, Peoples R China
[2] Tianjin Med Univ, Grad Sch, Tianjin, Peoples R China
[3] Anhui Med Univ, Anhui Prov Hosp, Dept Hepat Surg, Hefei, Anhui, Peoples R China
关键词
interferon; hepatitis C virus; hepatitis B virus; hepatocellular carcinoma; survival; CHRONIC HEPATITIS-C; ADVANCED LIVER-DISEASE; B-VIRUS; PEGINTERFERON ALPHA-2A; CLINICAL-TRIALS; PLUS RIBAVIRIN; CIRRHOSIS; THERAPY; LAMIVUDINE; CANCER;
D O I
10.1002/ijc.25767
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Available literature on the effects of interferon (IFN) treatment on development and progression of hepatocellular carcinoma (HCC) in patients with chronic virus infection reports controversial results. The primary objective of this meta-analysis was to evaluate the effect of IFN on HCC risk in patients with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection; IFN's efficacy on local tumor progression and survival of advanced HCC patients was also assessed. All randomized controlled trials (RCTs) comparing IFN with no antiviral treatment were selected. Finally, we identified 11 RCTs including 1,772 patients, who met our inclusion criteria to perform this meta-analysis. Our analysis results showed that IFN significantly decreased the overall HCC incidence in HCV-infected patients [relative risk (RR) = 0.39; 95% confidence interval (CI) = 0.26-0.59; p = 0.000], subgroup analysis indicated that IFN decreased HCC incidence in HCV-related cirrhotic patients evidently (RR = 0.44; 95% CI = 0.28-0.68; p = 0.000); but HCC incidence in nonresponders to initial antiviral therapy did not reduce by maintenance IFN therapy (RR = 0.96; 95% CI = 0.59-1.56; p = 0.864). Analysis results also demonstrated that IFN did not significantly affect the overall rate of HCC in HBV-infected patients although there was a trend favoring IFN therapy (RR = 0.23; 95% CI = 0.05-1.04; p = 0.056). Besides, IFN did not improve one-year overall survival of advanced HCC patients significantly (RR = 1.61; 95% CI = 0.96-2.69; p = 0.072); however, a quantitative analysis on local tumor progression could not be performed owing to lack of unified definitions among trials included in our study. By this meta-analysis, we conclude that IFN therapy is effective in reducing overall HCC risk in chronic HCV-infected patients; using it in this subpopulation seems promising, but its administration in other subpopulations still requires further exploration.
引用
收藏
页码:1254 / 1264
页数:11
相关论文
共 50 条
  • [1] Colchicine versus PEG-interferon alfa 2b long term therapy: Results of the 4 year copilot trial
    Afdhal, N. H.
    Levine, R.
    Brown, R., Jr.
    Freilich, B.
    O'Brien, M.
    Brass, C.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 : S4 - S4
  • [2] [Anonymous], J VASC INTERV RADIOL
  • [3] Bernardinello E, 1999, HEPATO-GASTROENTEROL, V46, P3216
  • [4] Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis
    Breitenstein, S.
    Dimitroulis, D.
    Petrowsky, H.
    Puhan, M. A.
    Muellhaupt, B.
    Clavien, P. -A.
    [J]. BRITISH JOURNAL OF SURGERY, 2009, 96 (09) : 975 - 981
  • [5] PEGINTRON MAINTENANCE THERAPY IN CIRRHOTIC (METAVIR F4) HCV PATIENTS, WHO FAILED TO RESPOND TO INTERFERON/RIBAVIRN (IR) THERAPY: FINAL RESULTS OF THE EPIC3 CIRRHOSIS MAINTENANCE TRIAL
    Bruix, J.
    Poynard, T.
    Colombo, M.
    Schiff, E.
    Reichen, J.
    Burak, K.
    Heathcote, E. J. L.
    Berg, T.
    Poo-Ramirez, J. -L.
    Mello, C. Brandao
    Guenther, R.
    Niederau, C.
    Terg, R.
    Bopari, N.
    Harvey, J.
    Griffel, L. H.
    Burroughs, M.
    Brass, C. A.
    Albrecht, J. K.
    [J]. JOURNAL OF HEPATOLOGY, 2009, 50 : S22 - S22
  • [6] Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
    Buster, Erik H. C. J.
    Hansen, Bettina E.
    Buti, Maria
    Delwaide, Jean
    Niederau, Claus
    Michielsen, Peter P.
    Flisiak, Robert
    Zondervan, Pieter E.
    Schalm, Solko W.
    Janssen, Harry L. A.
    [J]. HEPATOLOGY, 2007, 46 (02) : 388 - 394
  • [7] Interferon and prevention of hepatocellular carcinoma in viral cirrhosis:: an evidence-based approach
    Cammà, C
    Giunta, M
    Andreone, P
    Craxì, A
    [J]. JOURNAL OF HEPATOLOGY, 2001, 34 (04) : 593 - 602
  • [8] Hepatitis B virus-related cirrhosis: Natural history and treatment
    Chu, CM
    Liaw, YF
    [J]. SEMINARS IN LIVER DISEASE, 2006, 26 (02) : 142 - 152
  • [9] Interferon - The magic bullet to prevent hepatocellular carcinoma recurrence after resection?
    Clavien, Pierre-A.
    [J]. ANNALS OF SURGERY, 2007, 245 (06) : 843 - 845
  • [10] Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
    Di Bisceglie, Adrian M.
    Shiffman, Mitchell L.
    Everson, Gregory T.
    Lindsay, Karen L.
    Everhart, James E.
    Wright, Elizabeth C.
    Lee, William M.
    Lok, Anna S.
    Bonkovsky, Herbert L.
    Morgan, Timothy R.
    Ghany, Marc G.
    Morishima, Chihiro
    Snow, Kristin K.
    Dienstag, Jules L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23) : 2429 - 2441